Samuel Thompson, MD
Internal Medicine · Lexington, KYNPI 1710483516
Payments from drug & device makers
Across 641 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- Amgen$853
- Novartis$800
- Lilly USA, LLC$767
- AstraZeneca$670
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 113 | $1,613 |
| AbbVie | 87 | $1,311 |
| Amgen(2 entities) | 48 | $853 |
| Novartis | 49 | $800 |
| Lilly USA, LLC | 56 | $767 |
| AstraZeneca | 28 | $670 |
| Johnson & Johnson | 33 | $511 |
| Boehringer Ingelheim | 31 | $409 |
| E.r. Squibb & Sons, L.L.C. | 38 | $377 |
| Pfizer | 23 | $315 |
| Sanofi-aventis U.S. LLC | 16 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $254 |
| Bayer | 15 | $240 |
| Axsome Therapeutics, Inc. | 8 | $200 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $197 |
| Sumitomo Pharma America, Inc. | 10 | $176 |
| Exact Sciences | 10 | $166 |
| Astellas Pharma US Inc | 9 | $160 |
| Biogen | 5 | $114 |
| Dexcom, Inc. | 5 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Amarin Pharma, Inc. | 3 | $50 |
| Inari Medical, Inc. | 1 | $39 |
| Corium, LLC | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Medtronic | 1 | $28 |
| Lundbeck LLC | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,970 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 222 | $241,726 |
| JardianceEmpagliflozin | 122 | $124,035 |
| EliquisApixaban | 127 | $121,093 |
| MounjaroTirzepatide | 80 | $100,882 |
| RybelsusSemaglutide | 48 | $77,436 |
| XareltoRivaroxaban | 73 | $76,593 |
| FarxigaDapagliflozin Propanediol | 61 | $68,515 |
| Repatha SureclickEvolocumab | 33 | $29,196 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $25,415 |
| MyrbetriqMirabegron | 13 | $17,154 |
| TrulicityDulaglutide | 13 | $13,590 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $10,611 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $10,207 |
| LinzessLinaclotide | 13 | $9,980 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,613 | $319,162270 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $409 | $139,972155 claims |
| PfizerEliquis | $315 | $121,093127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $767 | $114,47293 claims |
| Johnson & JohnsonXarelto | $511 | $76,59373 claims |
| AstraZenecaFarxiga | $670 | $68,51561 claims |
| Astellas Pharma US IncMyrbetriq | $160 | $17,15413 claims |
| AbbVieLinzess, Synthroid | $1,311 | $12,97857 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $269 | $10,61113 claims |
| GSKTrelegy Ellipta | $19 | $9,59611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Lexington
- Neil FarrisLexington$3M
- David ManninoLexington$168K
- John BordersLexington$166K
- Fadi BachaLexington$31K
- James BordersLexington$31K
- Jad BalloutLexington$30K
- Thomas von UnrugLexington$22K
- Danilo CoralesLexington$17K
- Mohamed TashaniLexington$17K
- Kelli TrentLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.